Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 May 30;9(5):e026380.
doi: 10.1136/bmjopen-2018-026380.

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

Emmanuel Cognat  1   2 , François Mouton Liger  1 , Anne-Cécile Troussière  3 , David Wallon  4   5 , Julien Dumurgier  2   6 , Eloi Magnin  7 , Emmanuelle Duron  8 , Audrey Gabelle  9 , Bernard Croisile  10 , Vincent de la Sayette  11 , Alain Jager  12 , Frederic Blanc  13   14 , Elodie Bouaziz-Amar  1   15 , Carole Miguet-Alfonsi  16 , Muriel Quillard  17   18 , Susanna Schraen  19 , Nathalie Philippi  20 , Emilie Beaufils  21 , Florence Pasquier  22   23 , Didier Hannequin  4   24 , Philippe Robert  25 , Jacques Hugon  1   2 , Claire Paquet  1   2 ; ePLM network
Affiliations
Multicenter Study

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

Emmanuel Cognat et al. BMJ Open. .

Abstract

Objectives: New diagnostic criteria for Alzheimer's disease (AD) include cerebrospinal fluid (CSF) biomarkers that allow diagnosis at the stage of mild cognitive impairment (MCI). However, the impact of CSF biomarkers in MCI populations in clinical practice has been poorly evaluated. The objective of this study is to assess the use and impact in clinical practice of AD CSF biomarkers in French memory clinics.

Design: We performed a nation-wide, prospective survey between March 2012 and September 2014. Data over the same period was extracted from the French National Database (Banque Nationale Alzheimer, BNA) and compared with the results of the survey.

Setting: 29 secondary and tertiary memory clinics in France.

Participants: Clinicians prescribing lumbar puncture (LP) in order to measure AD CSF biomarkers. Clinicians completed a two-part questionnaire for each of their patients undergoing LP.

Primary and secondary outcome measures: Assessment of diagnosis, level of confidence before and after CSF biomarkers and impact on management in patients who underwent LP for CSF AD biomarkers in clinical routine.

Results: 977 questionnaires were completed, of which 61 were excluded because of unknown initial/final diagnosis or non-contributory CSF results. Of 916 patients reported, 153 (16.7%) had MCI as the initial diagnosis, of which 51 (33.3%) displayed an AD profile. CSF biomarkers resulted in a change in diagnosis in 44 patients (28.8%). Confidence level significantly increased after LP (8.3±1.4vs 6.73±1.18, p<0.0001), and CSF results modified management in 71/156 patients (46.4%), including 36 (23.5%) enrolled in clinical trials. Comparison of change in diagnosis with the BNA population revealed no difference (32.24%, p=0.4).

Conclusion: This nation-wide survey, reflecting clinical practice in French memory clinics, describes the impact of CSF AD biomarkers in patients with MCI in clinical practice.

Keywords: Alzheimer’s disease; biomarkers; cerebrospinal fluid; clinical practice; mild cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flowchart. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment.
Figure 2
Figure 2
(A) Main diagnosis after CSF AD biomarkers, depending on the CSF profile in patients with MCI. (B) Confidence level in the proposed diagnosis before and after CSF AD biomarkers in the MCI population, depending on the CSF profile. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment.
See this image and copyright information in PMC

References

    1. Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 2011;7:270–9. 10.1016/j.jalz.2011.03.008 - DOI - PMC - PubMed
    1. Petersen RC, Smith GE, Waring SC, et al. . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–8. - PubMed
    1. Schoonenboom NS, Reesink FE, Verwey NA, et al. . Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012;78:47–54. 10.1212/WNL.0b013e31823ed0f0 - DOI - PubMed
    1. Tapiola T, Alafuzoff I, Herukka SK, et al. . Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382–9. 10.1001/archneurol.2008.596 - DOI - PubMed
    1. Dubois B, Feldman HH, Jacova C, et al. . Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29. 10.1016/S1474-4422(14)70090-0 - DOI - PubMed

Publication types